Home › Companies › Supernus Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Supernus Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Supernus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Supernus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Frederick M. Hudson | 45,058,634 | -- | -- | 2,177,068 | 3,073,181 | Majority: yes |
| Elect Director: Charles W. Newhall, III | 41,743,154 | -- | -- | 5,492,548 | 3,073,181 | Majority: yes |
| Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers. | 45,552,633 | 1,675,355 | 7,714 | -- | 3,073,181 | Majority: yes |
| Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026. | 49,882,228 | 417,336 | 9,319 | -- | 0 | Majority: yes |
| Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc | 41,925,692 | 5,302,088 | 7,922 | -- | 3,073,181 | Majority: yes |
Source: Supernus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-18 — read the filing on EDGAR.
Each item below shows how the 377 asset managers that disclosed a Supernus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Supernus Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-06-18.
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 78% for, 3% against (81% of the company cast a for/against vote).
The 367 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 8,513,480 | 878 | 0 | 0 | For |
| Vanguard | 7,060,541 | 12 | 0 | 0 | For |
| State Street | 2,139,354 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,829,285 | 0 | 0 | 0 | For |
| Loomis Sayles | 1,779,608 | 0 | 0 | 0 | For |
| Fidelity | 1,750,251 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,533,481 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,489,631 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| Charles Schwab | 1,345,242 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,168,784 | 0 | 0 | 0 | For |
| Renaissance | 1,108,266 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 21,276 | 0 | 0 | 0 | Split |
| Citadel | 861,525 | 0 | 0 | 0 | For |
| Dimensional | 844,267 | 0 | 0 | 0 | For |
| Northern Trust | 671,460 | 0 | 0 | 0 | For |
| Victory Capital | 652,909 | 0 | 0 | 0 | For |
| ASHFORD CAPITAL MANAGEMENT INC | 570,444 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 568,124 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 454,625 | 0 | 0 | 0 | For |
| Woodline Partners LP | 407,024 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 402,454 | 0 | 0 | 0 | For |
| Goldman Sachs | 400,254 | 0 | 0 | 0 | For |
| Invesco | 366,832 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 362,770 | 0 | 0 | Against |
Showing the 25 largest of 367 asset managers. See all 367 in the interactive database.
Meeting held 2026-06-18.
Combines 2 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 4: To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 41,925,692 for, 5,302,088 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 72% for, 9% against (81% of the company cast a for/against vote).
The 108 asset managers below cast 92% of the shares they voted on this item FOR (21,906,605 for, 1,946,172 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,575,557 | 17,346 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 2,338 | 999,590 | 0 | 0 | Against |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 0 | 312,681 | 0 | 0 | Against |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 186,124 | 21,276 | 0 | 0 | For |
| Brighthouse | 181,610 | 0 | 3,810 | 0 | For |
| Lincoln Financial | 140,218 | 36,390 | 0 | 0 | For |
| World Funds Trust | 0 | 167,126 | 0 | 0 | Against |
| American Century | 0 | 159,445 | 0 | 0 | Against |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 0 | 152,349 | 0 | 0 | Against |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Empower | 118,324 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 110,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. See all 108 in the interactive database.
Meeting held 2026-06-18.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Charles W. Newhall, III”): 41,743,154 for, 5,492,548 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 72% for, 9% withheld (81% of the company cast a for/withheld vote).
The 105 asset managers below cast 100% of the shares they voted on this item FOR (22,147,845 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,059 | 0 | 9,845 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 3,716 | 0 | 998,212 | 0 | Abstain |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 207,993 | 0 | Abstain |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 172,113 | 0 | 13,307 | 0 | For |
| Lincoln Financial | 136,521 | 0 | 40,087 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 131,115 | 0 | Abstain |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 77,744 | 0 | 32,300 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Meeting held 2026-06-18.
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026.”): 49,882,228 for, 417,336 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 86% for, 0.8% against (87% of the company cast a for/against vote).
The 105 asset managers below cast 99.9% of the shares they voted on this item FOR (23,897,570 for, 81 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,592,900 | 3 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 78 | 0 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 181,610 | 0 | 3,810 | 0 | For |
| Lincoln Financial | 176,608 | 0 | 0 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 110,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Meeting held 2026-06-18.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Frederick M. Hudson”): 45,058,634 for, 2,177,068 withheld, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 78% for, 4% withheld (81% of the company cast a for/withheld vote).
The 104 asset managers below cast 100% of the shares they voted on this item FOR (23,492,373 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,088 | 0 | 9,816 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 0 | 78 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 172,113 | 0 | 13,307 | 0 | For |
| Lincoln Financial | 172,911 | 0 | 3,697 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 131,115 | 0 | Abstain |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 77,744 | 0 | 32,300 | 0 | For |
Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.
Meeting held 2026-06-18.
96% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 78% for, 3% against (81% of the company cast a for/against vote).
The 5 asset managers below cast 100% of the shares they voted on this item FOR (65,550 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 40,755 | 0 | 0 | 0 | For |
| ADVISORY RESEARCH INC | 19,018 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 5,566 | 0 | 0 | 0 | For |
| Cornerstone Investment Partners, LLC | 208 | 0 | 0 | 0 | For |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma | 3 | 0 | 0 | 0 | For |
Meeting held 2025-06-16 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 45,796,936 for, 1,701,777 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 79% for, 3% against (82% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (10,483 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FORUM FUNDS II | 9,957 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 526 | 0 | 0 | 0 | For |
Meeting held 2025-06-16 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Carolee Barlow, M.D., Ph.D”): 46,104,993 for, 1,426,932 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 79% for, 2% withheld (82% of the company cast a for/withheld vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (10,483 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FORUM FUNDS II | 9,957 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 526 | 0 | 0 | 0 | For |
Meeting held 2025-06-16 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jack A. Khattar”): 46,511,003 for, 1,020,922 withheld, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 80% for, 2% withheld (82% of the company cast a for/withheld vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (10,483 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FORUM FUNDS II | 9,957 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 526 | 0 | 0 | 0 | For |
Meeting held 2025-06-16 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2025.”): 49,230,498 for, 310,868 against, per its Form 8-K filed 2025-06-17 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 85% for, 0.6% against (85% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (10,483 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FORUM FUNDS II | 9,957 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 526 | 0 | 0 | 0 | For |
Meeting held 2026-06-18.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (46,321 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Empower | 40,755 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 5,566 | 0 | 0 | 0 | For |
Meeting held 2026-06-18.
96% Majority: yes · of votes cast
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: To approve, on a non-binding basis, the compensation paid to our named executive officers.”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed 2026-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 58,039,721 outstanding shares: 78% for, 3% against (81% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (52 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Modern Wealth Management, LLC | 26 | 0 | 0 | 0 | For |
| Tandem Financial, LLC | 26 | 0 | 0 | 0 | For |
Ranked by the number of Supernus Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 58,039,721 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 14.67% |
| 2 | Vanguard | 12.17% |
| 3 | State Street | 3.69% |
| 4 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 3.15% |
| 5 | Loomis Sayles | 3.07% |
| 6 | Fidelity | 3.02% |
| 7 | ARMISTICE CAPITAL, LLC | 2.64% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.57% |
| 9 | Delaware/Macquarie | 2.50% |
| 10 | Charles Schwab | 2.32% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.16% | 13F |
| BlackRock, Inc. and its affiliates | 14.12% | DEF14A |
| Vanguard Group | 10.42% | 13F |
| Jack A. Khattar + | 6.78% | DEF14A |
| Millennium Management | 5.71% | 13F |
| Millenium Management LLC and its affiliates | 5.65% | DEF14A |
| Vanguard Portfolio Management | 5.62% | 13G |
| Armistice Capital, LLC | 4.76% | DEF14A |
| Dimensional Fund Advisors LP | 4.67% | DEF14A |
| State Street | 3.94% | 13F |
Percentages above are of 58,039,721 shares outstanding, as reported by Supernus Pharmaceuticals, Inc. on its Form 10-Q dated 2026-04-28 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Supernus Pharmaceuticals, Inc.’s 10-Q dated 2026-04-28. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Supernus Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 377 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,306 separate fund positions. Their filings are grouped here into 12 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding basis, the compensation paid to our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Supernus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-18.
Supernus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).